We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Biodesix Announces Phase 3 Clinical Trial Collaboration with Kadmon
News

Biodesix Announces Phase 3 Clinical Trial Collaboration with Kadmon

Biodesix Announces Phase 3 Clinical Trial Collaboration with Kadmon
News

Biodesix Announces Phase 3 Clinical Trial Collaboration with Kadmon

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Biodesix Announces Phase 3 Clinical Trial Collaboration with Kadmon"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Biodesix Inc. announce a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 non-small cell lung cancer (NSCLC) study of Kadmon’s KD019, a reversible tyrosine kinase inhibitor (TKI) targeting EGFR, HER2, VEGFR2 & 3, and SRC.

The study incorporates an exploratory analysis using VeriStrat, a commercially available, blood-based test that is currently used to help physicians guide treatment for patients with non-small cell lung cancer. VeriStrat testing will be performed on serum samples from the study to assess the test’s utility in identifying patients with better or worse outcomes following treatment with KD019. As a multiple TKI with superior potency against wild-type EGFR, KD019 is designed to improve overall survival compared to erlotinib.

“We are very pleased to work with Kadmon on this program,” commented Paul Beresford, Ph.D., Biodesix’ Vice President of Business Development and Strategic Marketing. “Our successful collaboration may bring a personalized approach to this exciting new therapy.”

Over the past year Biodesix has forged multiple partnerships with bio-pharmaceutical companies to examine VeriStrat’s utility with innovative oncology therapies and to discover novel diagnostic tests.

John Ryan, Ph.D., M.D., Chief Medical Officer of Kadmon, said, “This collaboration is aligned with our strategic vision to advance leading-edge science and therapies targeting multiple pathways of proliferation and survival in disease.”

Advertisement